long intergenic non-protein coding RNA 709Genealiases: []
Q-omics provides the consensus-scored LINC00709 profile across patient tissues and cancer cell-line models. LINC00709 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LINC00709 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, LINC00709 RNA expression shows 6,685 significant gene co-expression associations, with the highest sampling consensus in BLCA. Together, these results highlight BLCA, and KIRC as cancer lineages where LINC00709 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00709 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00709 survival associations across molecular data types. LINC00709 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00709 RNA expression–survival associations across cancer types. High LINC00709 expression shows unfavorable associations in UCEC, COAD, HNSC, ESCA and STAD, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for LINC00709 RNA expression.
This table summarizes LINC00709 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00709. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00709 shows lower tumor expression in KIRC. The KIRC box plot shows higher LINC00709 RNA expression in normal versus tumor tissue (log2 FC = −0.010, t-test p = .036).
This table shows molecular features associated with LINC00709 in patient tissues and cancer cell lines. In patient samples, LINC00709 shows the broadest associations at the RNA and protein expression levels, with BLCA recurring as the lineage with the largest associated feature set.
